• Mendoza LaddAntonioAFrom the Department of Medicine, Division of Gastroenterology, the Division of Biostatistics & Epidemiology, and the Division of Biostatistics, Texas Tech University Health Sciences Center at El Paso, and the Paul L. Foster School of M, Yi Jia, Christine Yu, Sherif Elhanafi, Alok Dwivedi, Jiayang Liu, Giangqing Song, Mark Hall, and Marc J Zuckerman.
• From the Department of Medicine, Division of Gastroenterology, the Division of Biostatistics & Epidemiology, and the Division of Biostatistics, Texas Tech University Health Sciences Center at El Paso, and the Paul L. Foster School of Medicine, Texas Tech University, El Paso.
• South. Med. J. 2016 Dec 1; 109 (12): 792-797.

ObjectivesInformation regarding Hispanics with inflammatory bowel disease (IBD) is scarce. In this study we aimed to describe a predominantly Hispanic population with IBD in a city located along the US-Mexico border and to identify clinical or demographic differences between Hispanics and non-Hispanics.MethodsRetrospective cohort analysis of patients with IBD between 2003 and 2013 at a tertiary care center. Information collected included age, sex, ethnicity, diagnosis, diagnosis status (new vs old), endoscopic extent of disease (EOD), extraintestinal manifestations, medical treatment, and surgeries performed. Continuous and categorical variables were compared using a two-sided unpaired t test/Wilcoxon rank sum test and the Fisher exact test, respectively. Results with P ≤ 5% were considered statistically significant.ResultsHispanics accounted for 71% of the population sample. A total of 141 patients (68%) were diagnosed as having ulcerative colitis (UC) and 67 (32%) as having Crohn disease (CD). The only statistically significant differences between Hispanics and non-Hispanics were older age at diagnosis and a higher proportion of new diagnoses in Hispanics with CD (P = 0.008 and 0.009, respectively) The most common EOD in patients with UC was extensive colitis, whereas isolated colonic disease predominated in CD, regardless of ethnicity. Immunomodulators and biologics were used in 3% and 1% of cases, respectively. Treatment regimens were similar in both ethnic groups. Patients with CD were more likely than those with UC to have undergone surgery (27% vs 11%, P = 0.004). Surgery rates did not differ between Hispanics and non-Hispanics.ConclusionsIn our population, UC was more common than CD, and the EOD of both conditions differed from the one previously described in other Hispanic populations in the United States. The use of immunomodulators and biologics is the lowest reported to date in the country. No clinically relevant differences were seen between Hispanics and non-Hispanics.

32 keywords...

hide…